Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interleukin-2 (IL-2) immunotherapy.

M G Macey1, D H Johnston

  • 1Department of Haematology, London Hospital, England, UK.

Medical Laboratory Sciences
|July 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Minimal residual disease detection with tumor-specific CD160 correlates with event-free survival in chronic lymphocytic leukemia.

Blood cancer journal·2015
Same author

Flow cytometric analysis of microparticle phenotype and their role in thrombin generation.

Cytometry. Part B, Clinical cytometry·2010
Same author

Platelet activation and endogenous thrombin potential in pre-eclampsia.

Thrombosis research·2009
Same author

Present state and future needs.

The Journal of the College of General Practitioners·2009
Same author

The role of natural killer T (NKT) cells in immune thrombocytopenia: is strong in vitro NKT cell activity related to the development of remission?

British journal of haematology·2005
Same author

Synthesis and characterization of the dimethyl-substituted bisbenzimidazole ligand and its manganese complex.

Inorganic chemistry·2003
Same journal

Bovine spongiform encephalopathy (BSE): a stimulus to wider research.

Medical laboratory sciences·1992
Same journal

HBsAg vaccinaemia in a newborn.

Medical laboratory sciences·1992
Same journal

Clinical waste disposal.

Medical laboratory sciences·1992
Same journal

Stereomicroscopy in clinical microbiology.

Medical laboratory sciences·1992
Same journal

Diagnostic dilemmas in acutely ill elderly people.

Medical laboratory sciences·1992
Same journal

Principal alterations to drug kinetics and dynamics in the elderly.

Medical laboratory sciences·1992
See all related articles

Recombinant interleukin-2 (IL-2) immunotherapy has become a key treatment for cancer patients. This discussion reviews the advancements and progress in IL-2 immunotherapy applications over the last five years.

Area of Science:

  • Oncology
  • Immunology
  • Biotechnology

Background:

  • Immunotherapy represents a significant advancement in cancer treatment.
  • Recombinant interleukin-2 (IL-2) has been a widely utilized agent in various cancer immunotherapy regimens.
  • The past five years have seen notable developments in the application of IL-2 in clinical settings.

Purpose of the Study:

  • To discuss the progress of interleukin-2 (IL-2) immunotherapy.
  • To provide an overview of IL-2's role in cancer treatment regimes.
  • To highlight advancements in IL-2 based cancer therapies.

Main Methods:

  • Literature review of immunotherapy applications.
  • Analysis of clinical data regarding IL-2 usage.
  • Discussion of treatment regimes incorporating IL-2.

Related Experiment Videos

Main Results:

  • Interleukin-2 (IL-2) has been extensively employed in cancer immunotherapy.
  • Progress in IL-2 immunotherapy has been observed over the last five years.
  • IL-2 continues to be a relevant therapeutic option in oncology.

Conclusions:

  • Interleukin-2 (IL-2) immunotherapy has demonstrated progress and utility in cancer treatment.
  • Continued research and application of IL-2 are important for advancing cancer care.
  • IL-2 remains a cornerstone in the evolving landscape of cancer immunotherapy.